A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase.

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apricitabine (Primary) ; Lamivudine
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Sponsors Novita Healthcare

Most Recent Events

27 Jul 2020 This trial has been completed in UK - MHRA as reported by European Clinical Trials Database record.
21 Apr 2012 Additional location (Germany) added as reported by European Clinical Trials Database record.
24 Mar 2012 Additional locations (France. United Kingdom and Portugal) added as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight